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Abstract 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta lactamases that are capable of 
hydrolysing beta-lactams except carbapenems and cephamycins. The most common ESBL types include CTX-
M, TEM and SHV. This genetic diversity in the various ESBL-producing organisms may reflect characteristic 
differences in relation to pathogenesis, antibiotic resistance expression, response to therapy, transmission and 
infection control. This work sought to determine the characteristic antibiotic minimum inhibition concentrations 
(MICs) and antimicrobial sensitivity profile of CTX-M-type ESBLs in Accra. Hundred (100) DNA templates 
were extracted from ESBL-producing K. pneumoniae and E. coli isolates. The specific ESBL types were 
determined by polymerase chain reaction with specific primers and reaction conditions. The MICs of the 
antibiotics were determined using Vitek 2 Compact System (bioMérieux, Marcy I’Etoile, France). The results 
showed that CTX-M-type ESBL have cefotaxime MIC in the resistant range of >64 µg/ml. The CTX-M-type ß-
lactamases showed co-resistances to gentamicin (88.6%), tetracycline (71.4%), trimethoprim-sulphamethoxazole 
(98.6%).The resistance of CTX-M-type ESBL producing organisms to fluoroquinolones have been well 
established in this work with resistances in ciprofloxacin (71.4%) and norfloxacin (71.4%) with MIC90 being >4 
µg/ml and >16 µg/ml respectively. The beta-lactam-beta-lactamase inhibitor combination of piperacillin-
tazobactam was more susceptible to CTX-M-type ESBL than amoxicillin-clavulanate. Imipenem and amikacin 
has been established as the in vitro drug of choice for the management of organisms producing CTX-M-type 
ESBL in this present work. Efforts should be made to control the increasing prevalence of CTX-M-type 
producing organisms in the communities and hospital settings in Accra with their adverse multiple-drug 
resistance. 
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1.0 Introduction 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta lactamases that are capable of 
hydrolysing beta-lactams except carbapenems and cephamycins. They are inhibited by beta-lactamase inhibitors 
such as clavulanic acid, sulbactam and tazobactam. They have been found in the Enterobacteriaceae and other 
Gram-negative bacilli. ESBL producing isolates are predominantly Klebsiella pneumoniae and Escherichia coli. 
The most common ESBL isolated from clinical specimen are the CTX-M, SHV and TEM (Paterson and 
Bonomo, 2005).   
Because ESBL enzymes are plasmid mediated, the genes encoding these enzymes are easily 
transferable among different bacteria. Most of these plasmids not only contain DNA encoding ESBL but also 
carry genes conferring resistance to several non-beta-lactam antibiotics. Consequently, most ESBL isolates are 
not only resistant to penicillins, cephalosporins and monobactams but also to other classes of antibiotics 
including aminoglycosides, fluoroquinolones, tetracyclines, nitrofurantoin and sulfamethoxazole-trimethoprim. 
Treatment of these multiple drug-resistant organisms has proven to be a therapeutic challenge (Todar, 2008). 
The specific ESBL-producing organisms have different genetic characteristics which mark their 
identification at the molecular level. This genetic diversity in the various ESBL-producing organisms may reflect 
characteristic differences in relation to pathogenesis, antibiotic resistance expression, response to therapy, 
transmission and infection control. Unfortunately, there is no published work on the antimicrobial resistance 
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characteristics of the ESBL types in Accra. This work seeks to determine the characteristic antibiotic minimum 
inhibition concentrations (MICs) and antimicrobial sensitivity profile of CTX-M-type ESBLs in Accra.  
 
2.0 Materials and Methods 
2.1 Materials 
Glycerol broth, blood agar and MacConkey agar were prepared according to manufacturers’ guidelines. Vitek 2 
Compact System (bioMérieux, Marcy I’Etoile, France) was used to identify the isolates, determine minimum 
inhibition concentration (MIC) of selected antibiotics and interpret the MICs according to CSLI breakpoints. 
Water bath was used to heat the colony suspension and centrifuge was used to spin the suspension to extract the 
bacteria DNA. BIOR GenePro thermocycler was used to perform the polymerase chain reaction (PCR) under 
controlled reaction conditions with specific primers.  PCR products were used to perform agarose gel 
electrophoresis with 1X TAE buffer, 2% agarose gel and 0.5µg/ml ethidium bromide at 120V for 45minutes. The 
bands on the gels were visualized by ultraviolet trans-illumination and photographed using a Kodak EDAS 290 
gel documentation system.  
2.2 Study Sites 
Lactose fermenting bacterial isolates were collected from the Central Laboratory of the Korle Bu Teaching 
Hospital (KBTH) and Advent Clinical Laboratories; both in the Accra Metropolis, Ghana. The PCR was 
performed at the molecular biology laboratory of the School of Allied Health Sciences, University of Ghana and 
the bands on the gels were visualized and photographed at the molecular biology laboratory of the Microbiology 
Department of University of Ghana Medical School.  
2.3 Sample Size 
A sample size of 70 CTX-M-type- producing K. pneumoniae and E. coli isolates. 
 
2.4 Inclusion Criteria 
Non-duplicate pure cultures of ESBL-producing K. pneumoniae and E. coli isolates were used in the work. 
 
2.5 Exclusion Criteria 
All isolates not confirmed as ESBL-producing K. pneumoniae and E. coli were excluded. 
 
 
2.6 Molecular Determination of CTX-M ESBL-coding Genes 
The molecular investigations of the CTX-M ESBL-coding genes included extraction of DNA template from the 
phenotypic ESBL-producing isolates by boiling method, preparation of the PCR reaction mixture using 
appropriate primers, standard PCR reaction in a thermocycler,   agarose gel electrophoresis, bands visualization 
by ultraviolet trans-illumination and bands photography using a Kodak EDAS 290 gel documentation system  
 
2.6.1 Genomic DNA Extraction of K. pneumoniae and E. coli 
DNA template was extracted by a simple boiling method. A loopful of bacterial colony was picked from each 
isolate and suspended in 100µl of double distilled H2O in Eppendorf tube. The DNA suspension was incubated 
at 99°C for 5 minutes and snapped cold on ice for 10 minutes. The cell lysate was then centrifuged briefly at 
high speed (12.000 rpm for 3 min), and the supernatant containing genomic DNA was transferred into sterile 
Eppendorf and 5µl of the supernatant was used for PCR reaction. The extracted DNA was stored at -21°C until 
required for PCR. 
 
2.6.2 PCR Detection of CTX-M ESBL-encoding Gene 
Polymerase chain reaction of CTX-M ESBL-encoding genes was carried out using BIOER GenePro 
thermocycler. A typical 25µl PCR reaction mixture for a primer set was prepared as shown in table 3. The 
primers used were already published primers as shown in table 1 and their corresponding PCR conditions (table 
2). Sterile distilled water as negative controls were included in each round of PCR. 
 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.4, No.12, 2014 
 
26 
Table 1: Primers used for the detection of ESBL genes (Heffernan et al., 2007) 
 
Primer name  Sequence (5'-3')                     Target Gene             Size(bp)   
                              
CTX-M-F         TTTGCGATGTGCAGTACCAGTAA         CTX-M                   590 
CTX-M-R         CGATATCGTTGGTGGTGCCATA 
 
 
 
  Table 2: PCR conditions used for the detection of ESBL genes (Heffernan et al., 2007) 
   
   Target Gene   PCR Condition 
 
   CTX-M
 
                   Initial denaturation for 5min at 94°C; 30 cycles of 94°C for 30s, 60°C for 30s,  
                                   72°C for 60s; Final extension at 72°C for 7min. 
 
 
 
 
 Table 3: PCR reaction mixture 
Reagent Volume (µl) Final concentration 
Nuclease-free water  16.175 - 
10X PCR buffer + MgCl2 2.5 1X 
10mM DNTP mix 0.4 200 µM each 
10µM forward primer 0.4 0.2µM 
10µM reverse primer 0.4 0.2µM 
5U/µl Taq polymerase 0.125 0.5U 
Template DNA 5 (≤1 µg/reaction) 
TOTAL volume 25  
 
 
 
   
2.6.3 Agarose Gel Electrophoresis 
The buffer (1XTAE buffer) was prepared and subsequently used to prepare 2% agarose gel. The suspension was 
boiled in a microwave for 2 minutes. The molten agarose was allowed to cool to 60°C and stained with 3µl of 
0.5µg/ml ethidium bromide (which absorbs invisible UV light and transmits the energy as visible orange light). 
A comb was inserted into the slots of the casting tray and the molten agarose was poured into the tray. The gel 
was allowed to solidify for 20 minutes to form the wells. The 1XTAE buffer was poured into the gel tank to 
barely submerge the gel. Two microliter (2µl) of 10X blue gel loading dye (which gives colour and density to the 
samples to make it easy to load into the wells and monitor the progress of the gel) was added to 10µl of each 
PCR product and loaded into the wells. The 100bp DNA ladder was loaded into well 1. The gel was 
electrophoresed at 120V for 45 minutes using either a midi or a maxi gel system. The bands on the gels were 
visualized by ultraviolet trans-illumination and photographed using a Kodak EDAS 290 gel documentation 
system. The sizes of the PCR products were estimated by comparison with the mobility of a 100bp molecular 
weight ladder that was ran alongside experimental samples in the gel. 
2.7 Antibiotic Sensitivity Testing 
The Vitek 2 system (bioMérieux, Marcy I’Etoile, France) was used to determine the MIC of the selected 
antibiotics and their therapeutic significance. The 17 antibiotics used were ampicillin, amoxicillin/clavulanic 
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acid, piperacillin, piperacillin/tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, 
amikacin, gentamicin, ciprofloxacin, norfloxacin, tetracycline, nitrofurantoin and trimethoprim/ 
sulfamethoxazole.  
 
 
3.0 Results 
3.1 Antibiotic Susceptibility among Isolates with CTX-M ESBL Genes 
Of the 70 CTX-M ESBL-producing organisms, the number and percentage of isolates in the susceptible MIC 
breakpoint and the MIC at which 50% of the CTX-M ESBL producers were susceptible to a particular 
antimicrobial agent (MIC50) and MIC at which 90% of the CTX-M ESBL producers were susceptible to a 
particular antimicrobial agent (MIC90) were recorded in table 4 below: 
 
Table 4 Antibiotic Susceptible among Isolates with CTX-M ESBL genes (n=70)   
Antimicrobial Agent                No.(%) of Susceptible Isolates                MIC(µg/ml) 
                                                                                                                MIC50   MIC90 
Ampicillin                                           0(0.0)                            
Amoxicillin/Clavulanic acid             12(17.1)         8   8                                      
Piperacillin                                         0(0.0)                       -    -                          
Piperacillin/Tazobactam                    24(34.3)        ≤4       16   
Cefazolin                                            0(0.0)            -          - 
Cefoxitin                                            50(71.4)               ≤4         8 
Cefotaxime                                         0(0.0)           -            - 
Ceftazidime                                       13(18.6)            4    4                  
Cefepime                                           52(74.3)                   2    8 
Imipenem                                          70(100.0)         ≤1        ≤1                
Amikacin                                           67(95.7)         ≤2         16                                
Gentamicin                                         8(11.4)          ≤1        ≤1                                           
Ciprofloxacin                                    19(27.1)                  0.5          1  
Norfloxacin                                       20(28.6)            2    2                   
Tetracycline                                      17(24.3)                   ≤1         4                                            
Nitrofurantoin                                   23(32.9)                  ≤ 16       32                                                      
Trimethoprim/Sulfamethoxazole       1(1.4)           ≤20      ≤20         
MIC50: MIC at which 50% of the CTX-M ESBL were susceptible to a particular antimicrobial agent        
 
MIC90: MIC at which 90% of the CTX-M ESBL were susceptible to a particular antimicrobial agent                                 
 
3.3 Antibiotic Resistance among Isolates with CTX-M ESBL Genes 
Of the 70 CTX-M ESBL-producing organisms, the number and percentage of isolates in the resistant MIC 
breakpoint and the MIC at which 50% of the CTX-M ESBL producers were resistant to a particular 
antimicrobial agent (MIC50) and MIC at which 90% of the CTX-M ESBL producers were resistant to a particular 
antimicrobial agent (MIC90) were recorded in table 5 below: 
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Table 5 Antibiotic Resistance among Isolates with CTX-M ESBL genes (n=70)   
Antimicrobial Agent                              No. (%) in Resistant Ranges                       MIC (µg/ml) 
                                                 MIC50   MIC90 
Ampicillin                                     70(100.0)                  ≥32       ≥32                
 
Amoxicillin/Clavulanic acid         20(28.6)                 ≥32       ≥32                      
Piperacillin                                    70(100.0)                          ≥128      ≥128                                  
Piperacillin/Tazobactam               43(61.4)                ≥128      ≥128                     
Cefazolin                                      70(100.0)                          ≥64        ≥64                          
Cefoxitin                                       9(12.9)                              32          ≥64              
Cefotaxime                                    70(100.0)                          ≥64       ≥64           
Ceftazidime                                   30(42.9)                            ≥64       ≥64 
Cefepime                                       6(8.6)                                ≥64       ≥64 
Imipenem                                      0(0.0)                         -          - 
Amikacin                                       0(0.0)                       -          -       
Gentamicin                                    62(88.6)                  ≥16         ≥16          
Ciprofloxacin                                50(71.4)                  ≥4           ≥4                                                        
Norfloxacin                                   50(71.4)                  ≥16        ≥16                                                            
Tetracycline                                  50(71.4)                 ≥16        ≥16                                                  
Nitrofurantoin                               47(67.1)                 ≥512      ≥512                  
Trimethoprim/Sulfamethoxazole    69(98.6)                 ≥320     ≥320                                             
MIC50: MIC at which 50% of the CTX-M ESBL were resistant to a particular antimicrobial agent        
 
MIC90: MIC at which 90% of the CTX-M ESBL were resistant to a particular antimicrobial agent                                 
 
 
 
 
4.0 Discussion 
The genetic diversity in the various ESBL-producing organisms may reflect characteristic differences in relation 
to antibiotic resistance expression. This study sought to establish the minimum inhibition concentrations (MICs) 
of beta-lactams, beta-lactam/beta-lactamase inhibitor combinations and non-beta-lactams among CTX-M-type 
ESBL producers. It has been suggested that organisms producing CTX-M-type beta-lactamases typically have 
cefotaxime MICs in the resistant range (>64 µg/ml) (Paterson and Bonomo, 2005) as has been confirmed in this 
present study. In this study the CTX-M-type ESBL hydrolysed ceftazidime with 42.9% of its MIC in the 
resistant range of >64 µg/ml confirming the report of Sturenburg and colleagues (2004) that CTX-M-type 
ESBLs may actually hydrolyse ceftazidime and confer resistance to it. This was also corroborated by Poirel and 
colleagues (2001) as well as Ramdani-Bouguessa and colleagues (2006). On the other hand only 8.6% of the 
cefepime MIC were in the resistant range at variance with Tzouvelekis and colleagues who reported that CTX-
M-type beta-lactamases hydrolyse cefepime with high efficiency (Tzouvelekis et al., 2000).   
In this study, CTX-M-type ESBL showed co-resistances to gentamicin, tetracycline and 
trimethoprim/sulphamethoxazole and is confirmed in the findings of Ramdani-Bouguessa and others (2006) who 
established co-resistance of CTX-M-type ESBL in gentamicin and trimethoprim/sulphamethoxazole in Algeria. 
Ben Ami and colleagues (2006) also corroborated this study where CTX-M-producing E. coli were co-resistant 
to trimethoprim/sulphamethoxazole and gentamicin. According to Bonnet (2004), CTX-M-type ESBL co-
resistance to non-beta-lactams may be attributed to genetic structures such as sul1-type integrons.  
As in the studies by Pitout and Laupland (2008), Ben Ami (2006), this study confirms that strains 
producing CTX-M enzymes were substantially resistant to ciprofloxacin. These reports contradict the findings of 
Ramdani-Bouguessa and colleagues (2006) who recorded low resistance rate to ciprofloxacin in Algeria. In this 
study CTX-M ESBL producing isolates were resistant to piperacillin/tazobactam than amoxicillin/clavulanic 
acid. This contradicts the study of Bush and others (1993) that tazobactam exhibits greater inhibitory activity to 
CTX-M-type ESBL than clavulanic acid. 
This study has established that none of the CTX-M-type ESBL showed resistance to imipenem and 
amikacin which confirm them as the drug of choice for treating CTX-M-type ESBL-producing infections. This is 
consistent with the findings of Oteo and others (2010) and Sana and colleagues (2011) which concluded that 
imipenem and amikacin were ideal for the treatment of severe ESBL-producing organisms.  
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5.0 Conclusion 
The outcome of this work affirmed elevated resistances to gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, 
tetracycline, trimethoprim-sulphamethoxazole and the beta-lactam-beta-lactamase inhibitor combination of 
piperacillin-tazobactam and amoxicillin-clavulanate by K. pneumoniae and E. coli producing CTX-M-type 
ESBL. Imipenem and amikacin have been established as the in vitro drug of choice for the management of 
organisms producing CTX-M-type ESBL in this present work. Conscientious efforts should be made to arrest the 
public health menace of CTX-M-type ESBL producing organisms in the communities and hospital settings in 
Accra. 
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